Krystal Biotech vs Twist Bioscience
KRYS and TWST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and TWST compare
Krystal Biotech and Twist Bioscience are about the same size, with market caps of $9.8B and $9.6B.
Krystal Biotech grew revenue faster over the last twelve months (22.6% versus 19.2% for Twist Bioscience).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −31.7% at Twist Bioscience.
Twist Bioscience scores higher on the StockData Score (13 against 10 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | TWST |
|---|---|---|
| Size and price | ||
| Market cap | $9.8B | $9.6B |
| Share price | $332.29 | $152.78 |
| Change, 1 year | 79.6% | 374% |
| Change, 5 years | 548% | 12.4% |
| Beta (5Y) | 0.84 | 2.28 |
| Employees | 295 | 979 |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 41.6× | – |
| P/S | 22.3× | 22.2× (better) |
| P/B | 7.2× (better) | 21.5× |
| EV/EBITDA | 45.5× | – |
| P/FCF | 38.2× | – |
| FCF yield | 2.6% (better) | −0.97% |
| Fair value | $157.63 | $34.30 |
| Margin of safety | −111% (better) | −345% |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | 19.2% |
| Revenue growth, 5Y average | – | 33.1% |
| Net income growth (TTM) | 64.6% | – |
| EPS growth (TTM) | 62.2% | – |
| Profitability | ||
| Gross margin | – | 52.0% |
| Operating margin | 44.9% (better) | −33.6% |
| Net margin | 54.8% (better) | −31.7% |
| FCF margin | 58.5% (better) | −21.6% |
| Return on equity | 20.1% (better) | −29.6% |
| Return on invested capital | 45.3% (better) | −45.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.32 (better) | 2.67 |
| Altman Z-score | 43.30 (better) | 22.67 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 122% |
| Held by insiders | 17.2% | 2.3% |
| Insider net buying, 12 months | −$105M (better) | −$126M |
| Short interest, % of float | 14.2% | 17.3% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- TWST stock overview
- TWST income statement
- TWST valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.